<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04408924</url>
  </required_header>
  <id_info>
    <org_study_id>17583</org_study_id>
    <secondary_id>I3Y-MC-JPCY</secondary_id>
    <secondary_id>2020-000290-24</secondary_id>
    <nct_id>NCT04408924</nct_id>
  </id_info>
  <brief_title>Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <acronym>CYCLONE 1</acronym>
  <official_title>CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate how safe and effective abemaciclib is when given to participants&#xD;
      whose metastatic prostate cancer progresses after they had received several previous&#xD;
      treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">August 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 25, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline to Objective Radiographic Soft Tissue Disease Progression (Estimated up to 12 Months)</time_frame>
    <description>ORR: Percentage of Participants with Best Response of CR or PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic Progression-Free Survival (rPFS)</measure>
    <time_frame>Baseline to Radiographic Disease Progression or Death from Any Cause (Estimated up to 12 Months)</time_frame>
    <description>rPFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to Date of Death Due to Any Cause (Estimated up to 24 Months)</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Date of First Documented CR or PR to Date of Radiographic Disease Progression or Death from Any Cause (Estimated up to 12 Months)</time_frame>
    <description>DoR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), CR or PR</measure>
    <time_frame>Baseline to Radiographic Soft Tissue Disease Progression (Estimated up to 12 Months)</time_frame>
    <description>DCR: Percentage of participants who exhibit SD, CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen (PSA) Response Rate</measure>
    <time_frame>Baseline to Date of Treatment Discontinuation (Estimated up to 12 Months)</time_frame>
    <description>PSA Response Rate: Percentage of Participants with a PSA Decrease of at Least 50% from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA Progression</measure>
    <time_frame>Baseline to the Date of First Observation of PSA Progression (Estimated up to 12 Months)</time_frame>
    <description>Time to PSA Progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Symptomatic Progression</measure>
    <time_frame>Baseline to the Date of First Documented Symptomatic Progression (Estimated up to 12 Months)</time_frame>
    <description>Time to Symptomatic Progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Outcomes (PRO)</measure>
    <time_frame>Baseline to End of Study (Estimated up to 12 Months)</time_frame>
    <description>Patient-reported tolerability, including select symptomatic adverse events (from the PRO-Common Terminology Criteria for Adverse Events item library) and overall side-effect burden (item GP5 of the Functional Assessment of Cancer Therapy Tool General form (FACT-G))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Mean Steady State Concentration of Abemaciclib and its Metabolites</measure>
    <time_frame>Predose Cycle 1 Day 15 through Predose Cycle 3 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: Mean Steady State Concentration of Abemaciclib and its Metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Ki-67 Positive Cells by Immunohistochemistry (IHC)</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of Ki-67 positive cells by IHC</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metastatic Castration-Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Abemaciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Abemaciclib</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must have metastatic prostate cancer for which castration (medical or&#xD;
             surgical) is no longer effective (castration-resistant).&#xD;
&#xD;
          -  Participant must have disease spread to soft tissue that is measurable.&#xD;
&#xD;
          -  Participant must have documented evidence of progressive disease by PSA test or&#xD;
             imaging.&#xD;
&#xD;
          -  Participant must have previously received at least one of the following treatment:&#xD;
             abiraterone acetate, apalutamide, darolutamide or enzalutamide.&#xD;
&#xD;
          -  Participant must have previously received chemotherapy with docetaxel and cabazitaxel.&#xD;
&#xD;
          -  Participant must be willing and amenable to undergo a biopsy of tumor tissue (or able&#xD;
             to provide adequate archived tumor tissue sample) and to provide blood for research.&#xD;
&#xD;
          -  Participant must have good physical functioning ability and adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant must not have received more than 3 therapy regimens for metastatic&#xD;
             castration-resistant prostate cancer (NOTE: GnRHa, first-generation antiandrogens&#xD;
             (flutamide, nilutamide, or bicalutamide), diethylstilbestrol (DES) (or other&#xD;
             estrogens), corticosteroids, ketoconazole, and bone loss-prevention will not count as&#xD;
             systemic therapy regimens.&#xD;
&#xD;
          -  Participants must not have previously received abemaciclib or any cyclin-dependent&#xD;
             kinase (CDK)4 and/or CDK6 inhibitors.&#xD;
&#xD;
          -  Participants must not have serious and/or uncontrolled preexisting medical&#xD;
             condition(s) including but not limited to severe renal impairment, severe hepatic&#xD;
             impairment, interstitial lung disease (ILD)/pneumonitis, severe dyspnea at rest or&#xD;
             requiring oxygen therapy or other serious preexisting medical condition(s) that, in&#xD;
             the judgment of the investigator, would preclude participation in this study.&#xD;
&#xD;
          -  Participants must not have, or suspected to have, brain metastasis.&#xD;
&#xD;
          -  Participants must not have untreated spinal cord compression, evidence of spinal&#xD;
             metastases with risk of spinal compression or structurally unstable bone lesions&#xD;
             suggesting impending fracture.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah - Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacion Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/5ARvCmtBk1XeifKLCEUPWB</url>
    <description>Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer (CYCLONE 1)</description>
  </link>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mCRPC</keyword>
  <keyword>CDK4</keyword>
  <keyword>CDK6</keyword>
  <keyword>CDK4/6</keyword>
  <keyword>CDK4&amp;6 inhibitor</keyword>
  <keyword>CDK4/6 inhibitor</keyword>
  <keyword>LY2835219</keyword>
  <keyword>CYCLONE 1</keyword>
  <keyword>CYCLONE1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

